Full Breakdown
Isomorphic Labs Pursues Over $2 Billion to Scale AI-Powered Drug Discovery
5/9/2026, 11:22:14 AM
Isomorphic Labs Seeks Over $2 Billion in New Funding
Isomorphic Labs, an AI-driven drug discovery company spun out of Alphabet’s Google DeepMind, is in advanced talks to raise more than $2 billion. Thrive Capital, which led its 2025 $600 million round, will lead the new financing, with Alphabet also expected to participate. The round is not yet closed.
From AlphaFold to Commercial Drug Design
Formed in 2021, Isomorphic Labs builds on DeepMind’s AlphaFold system that predicts protein structures. The spinout aims to translate AlphaFold’s scientific breakthroughs into a drug-design engine that can generate candidate molecules faster and at lower cost than traditional methods.
Principal Figures and Corporate Stakeholders
DeepMind chief executive Demis Hassabis also runs Isomorphic Labs. Venture firm Thrive Capital is the lead investor, while Alphabet and its venture arm GV have previously contributed. The company has secured research collaborations with Johnson & Johnson, Eli Lilly & Co., and Novartis.
Funding Scale and Prior Capital
The targeted raise exceeds $2 billion, dwarfing the $600 million Series A round closed in March 2025. That earlier round included participation from Thrive Capital, Alphabet, and GV, and was tied to potential milestone payments of nearly $3 billion from its Eli Lilly and Novartis collaborations.
Official Statements and Investor Responses
Representatives for Thrive Capital and Isomorphic Labs declined to comment on the pending round. Alphabet and Google also did not respond to requests for comment. The lack of public statements underscores the confidential nature of the financing discussions.
Criticisms and Market-Structure Concerns
Analysts note that AI drug discovery remains a slow, regulated, and costly endeavor, requiring laboratory testing, toxicology, human trials, and regulatory approval. They warn that high capital demands may create a winner-take-most market, favoring platforms with deep-pocketed investors or strategic parents like Alphabet, while smaller startups may struggle.
Conflicting Details and Information Gaps
Sources agree the raise aims for “more than $2 billion,” but no precise amount or closing timeline is disclosed. Additionally, while Thrive Capital is identified as the lead investor, the extent of Alphabet’s participation remains unspecified.
Why It Matters: Potential Impact on AI-Biotech
If successful, the funding could accelerate Isomorphic Labs’ drug-design engine, enabling faster candidate generation and potentially lowering development costs. The move also signals a shift in AI investment toward longer-term, high-value sectors such as healthcare, where commercial returns depend on clinical success rather than immediate software adoption.
What’s Next
Closing the round will allow Isomorphic Labs to expand its drug-design platform globally and to advance internal programs toward clinical trials. Observers will watch whether the capital translates into tangible drug candidates and how the company’s progress influences broader AI-driven biotech financing.
